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Abstract
Introduction
Familial history of melanoma is a well-known risk factor for the disease, and 7%melanoma
patients were reported to have a family history of melanoma. Data relating to the frequency
and clinical and pathological characteristics of both familial and non-familial melanoma in
Spain have been published, but these only include patients from specific areas of Spain
and do not represent the data for the whole of Spain.
Patients andmethods
An observational study conducted by the Spanish Group of Melanoma (GEM) analyzed the
family history of patients diagnosed with melanoma between 2011 and 2013 in the derma-
tology and oncology departments.
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Results
In all, 1047 patients were analyzed, and 69 (6.6%) fulfilled criteria for classical familial mela-
noma (two or more first-degree relatives diagnosed with melanoma). Taking into account
other risk factors for familial melanoma, such as multiple melanoma, pancreatic cancer in
the family or second-degree relatives with melanoma, the number of patients fulfilling the
criteria increased to 165 (15.8%). Using a univariate analysis, we determined that a Breslow
index of less than 1 mm, negative mitosis, multiple melanoma, and a history of sunburns in
childhood were more frequent in familial melanoma patients, but a multivariate analysis re-
vealed no differences in any pathological or clinical factor between the two groups.
Conclusions
Similar to that observed in other countries, familial melanoma accounts for 6.6% of melano-
ma diagnoses in Spain. Although no differences in the multivariate analysis were found,
some better prognosis factors, such as Breslow index, seemmore frequent in familial mela-
noma, which reflect a better early detection marker and/or a different biological behavior.
Introduction
Melanoma risk is determined by several factors, including sun exposure (for cutaneous mela-
noma), individual phenotype (phototype, presence of multiple and/or atypical nevi), and famil-
ial background. Rare genetic conditions such as xeroderma pigmentosus or hereditary
retinoblastoma increase the risk for cutaneous melanoma. In a recent meta-analysis, the pres-
ence of familial aggregation of melanoma is estimated to account for 1.3–15.8% of melanoma
cases, depending on the series and the countries studied [1]. Approximately 25% of these famil-
ial cases can be explained by germline mutations in cyclin-dependent kinase inhibitor 2A
(CDKN2A), the most frequent gene mutated in familial melanoma, revealing that the genetic
explanation for the majority of cases remains elusive [2,3]. Patients with CDKN2Amutations
have a high risk of developing melanoma, as well as other tumors, the most common of which
is pancreatic cancer [4]. Genetic counseling for these patients is under debate, since the real im-
pact of prevention or early diagnosis remains unclear [5,6]
Familial melanoma is generally defined as the occurrence of melanoma in two or more first-
degree relatives (in areas of heavy sun exposure, such as Australia it must be three first degree
relatives) [7,8]. However, other features are considered by other researchers: both first-degree
and second-degree; presence in the family of pancreatic cancer; and the presence in the same
patient of multiple melanoma [2,3].
Since melanoma is a malignant tumor with one of the fastest growing incidence rates in the
Western world, knowing the general epidemiological landscape, including the proportion of
high-risk melanoma families, is of interest, particularly in terms of prevention, early detection,
and design of public health plans.
Currently, no studies have analyzed the frequency of familial melanoma cases in Spain.
Since these data are lacking, the Spanish Multidisciplinary Group of Melanoma (GEM) de-
signed the FAM-GEM-1 study, with the aim of describing the frequency and characteristics of
familial melanoma in Spain in a representative population sample.
The principal objectives of this study were to calculate the frequency of familial melanoma
and to describe the clinical and pathological characteristics of familial and non-familial
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melanoma patients. The secondary objectives were to analyze potential differences between
classic familial and non-familial melanoma patients and to calculate the frequency of patients
with non-classic melanoma risk factors (multiple melanoma, melanoma and pancreatic cancer
in the family, melanoma in second-degree relatives) distinct from those patients with more
classic indications of familial melanoma.
Patients and Methods
FAM-GEM-1 is an observational, national registry study. All GEM-associated investigators
were invited to participate in this study. To meet the inclusion criteria patients must have been
18 years old, diagnosed with melanoma (both incident and prevalent cases) and have signed
informed consent. The inclusion period ranged from October 2011 to October 2013. A ques-
tionnaire was completed by the patients’ attending physician and included data regarding per-
sonal, phenotypical, pathological, and familial features. A pathology report from the patient
was mandatory; pathology reports from relatives were not mandatory, but recommended. Pa-
tients with familial melanoma were asked if the melanoma of their relative or relatives was di-
agnosed before their own diagnosis.
Definitions
Familial melanoma was defined as the presence of two or more first-degree relatives with mela-
noma. Multiple melanoma was defined as the presence in the same patient of two or more in-
vasive melanomas (independent of the histological subtype and the time of appearance) and no
incidences of familial melanoma. Pancreatic and melanoma in the family was defined as the
presence of pancreatic cancer and no incidences of familial melanoma. Second-degree melano-
ma was defined as the occurrence of melanoma in at least one second-degree relative and no
incidences of familial melanoma.
Statistical analysis
Fisher exact test or unpaired Student t test were performed for categorical or continuous vari-
ables comparison, respectively. A p-value<0.05 was considered statistically significant. Uni-
variate and multivariate analyses were performed to determine if independent variables were
associated with familial melanoma or non-classic familial melanoma. A p-value<0.25 in the
univariate analysis for categorical variables was used to select variables of interest for the multi-
variate analysis. SPSS v 21 program (IBM Corporation) was used to perform the analyses.
Investigation ethical committee review board from Hospital General Universitario Gregorio
Marañon (central site) approved the study. Approval from local participant institutions was
obtained at each site according to Spanish regulation. This study was conducted in accordance
with the ethical principles of the Declaration of Helsinki. All the participants provided their
written consent to participate in this study.
Results
Primary objectives: frequency and characteristics of familial melanoma
From October 2011 to October 2013, 1047 consecutive patients, from 10 different Spanish re-
gions (Andalucía, Aragon, Asturias, Cataluña, Comunidad Valenciana, Galicia, Madrid, Mur-
cia, Navarra, and La Rioja) were recruited to participate in the study (Table 1). In all, 685
(65.4%) and 362 (34.6%) patients were recruited in the dermatology and medical oncology de-
partments, respectively. Data were collected by 25 investigators from 21 different institutions.
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In all, 69 patients (6.6%) fulfilled the criteria for familial melanoma. Table 2 describes the
clinical, pathological, and familial characteristics of the population, and these variables were
compared using univariate analysis.
Forty-seven familial melanoma patients (68.1%) reported that their melanoma was diag-
nosed after the diagnoses of their relative or relatives, while 17 patients (24.6%) described their
diagnosis as occurring prior to that of their relative or relatives, and 5 patients (0.5%) could not
report it.
Secondary objectives
Frequency of other hereditary melanoma risk factors. Taking into account other mela-
noma risk factors, 96 patients (9.2%) fulfilled one of the following risk criteria: 24 patients
(2.3%) reported occurrence of melanoma in second-degree, but not first-degree relatives; 32
patients (3.1%) were diagnosed with multiple melanoma; 35 (3.3%) reported pancreatic cancer
in the family; and 5 (0.5%) fulfilled more than one of these criteria.
Multivariate analysis for familial melanoma
In order to investigate if there were any independent clinical or pathological characteristics de-
scribed in the univariate analysis that associated with familial melanoma, a multivariate binary
logistic regression analysis was conducted. Variables chosen included those whose p values in
the univariate analysis were<0.25 (Table 2). Neither sex, multiple nevi, sunburn in childhood,
multiple melanoma, Breslow, mitosis, node status, nor metastases were associated with familial
melanoma (Table 3). A trend (p = 0.097) was detected between multiple and familial melanoma.
Discussion
In this national registry study, with a representative sample of the Spanish population, we
found a 6.6% frequency of familial melanoma, defined as the presence of two or more first-de-
gree relatives with melanoma. After expanding the definition to less restrictive criteria, as pro-
posed by other authors [2], the frequency of familial melanoma patients increased to 15.8%.
There are many limitations of this study that must be taken into account in order to properly
interpret the results. First, the study aimed to cover all Spanish territory, but we do not have pa-
tient data from 7 of the 17 regions that constitute the Spanish territory. In addition, Madrid
(Center) and Valencia (East) contribute to 712 of the 1047 patients, which is more than two
thirds. Data from more areas with heavy sun exposure, such as the Canary Islands (South) and
the Balearic Islands (East), would have been of interest to complete the epidemiological picture.
Table 1. Distribution of familial melanoma across different regions in Spain.
SPAIN’S REGION FAMILIAL MELANOMA RATIO (%)
GALICIA (NORTH-WEST) 1/19 (5.3)
ASTURIAS (NORTH-WEST) 2/66 (3)
NAVARRA (NORTH) 6/70 (8.6)
ARAGON (NORTH) 1/30 (3.3)
MADRID (CENTER) 41/480 (8.5)
LA RIOJA (NORTH) 1/32 (3.1)
CATALUÑA (NORTH-EAST) 4/64 (6.3)
VALENCIA (EAST) 11/232 (4.7)
MURCIA (SOUTH-EAST) 0/26 (0)
ANDALUCIA (SOUTH) 2/28 (7.1)
doi:10.1371/journal.pone.0124239.t001
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Second, a possible selection bias could not be excluded, even though the study included all
patient diagnosed as having melanoma. Our result of 6.6% is close to the frequency described
in meta-analyses [1], suggesting that the possibility of this bias is less probable.
Third, a melanoma pathology report for relatives was not mandatory, but recommended.
This again could be a source of bias, especially since the presence of skin diseases can usually
be confounded. For this reason, our study design limited the definition of familial melanoma
only to patients having first-degree relatives diagnosed with melanoma, in order to avoid this
bias. However, we believe that these results can be extrapolated to the real-world practice set-
ting, where the pathology report of a given relative is not always available.
Notably, Madrid (Center) and Navarra (North) had almost double the frequency of
familial melanoma (8.5% and 8.6%, respectively) as did Valencia (4.7%), the second region in
Table 2. Clinical and pathological characteristics of familial and non-familial melanoma patients.
CLINICAL/PATHOLOGICAL CHARACTERISTIC FAMILIAL MELANOMA N (%) 69/
1047 (6,6)
NON FAMILIAL MELANOMA N(%) 978/
1047 (93,4)
p VALUE
AGE mean (SD) 52.5 (15.4) 55.2 (16.3) 0.1824
AGE UNDER 50 29/69 (42) 357/978 (36.5) 0.3681
SEX (MALE) 40/69 (58) 489/978 (50) 0.2145
PHOTOTYPE I-II 32/68 (47.1) 482/971 (49.6) 0.7081
RED-BLOND HAIR 17/68 (25) 191/963 (19.8) 0.3471
FAIR EYES COLOUR 24/68 (35.3) 363/968 (37.5) 0.7958
FRECKLES 17/67 (25.4) 308/960 (32.1) 0.2795
MULTYPLE NEVI 18/67 (26.9) 195/955 (20.4) 0.2143
INTERMITENT SUN EXPOSURE (SUNBED
INCLUDED)
39/69 (56.5) 560/978 (57.3) 0.9006
CHRONIC SUN EXPOSURE 16/69 (23.2) 189/978 (19.3) 0.4337
SUN BURNS IN CHILDHOOD 51/66 (77.3) 580/962 (60.3) 0.0059
MELANOMA IN PREVIOUS NEVUS 22/65 (33.8) 265/883 (30) 0.5759
MULTIPLE MELANOMA 6/69 (8.7) 35/978 (3.6) 0.0471
NON-SKIN MELANOMA (INCLUDING ACRAL) 7/69 (10.1) 112/978 (11.5) 0.8466
IN SITU MELANOMA 8/53 (15.1) 95/762 (12.5) 0.5254
BRESLOW (mm), mean (SD) 1.55 (1.77) 2.27 (2.68) 0.0544
BRESLOW >1 mm 23/53 (37.7) >1 mm: 459/762 (61.2) 0.0022
<1 mm:30/53 (62.3) <1mm: 303/762 (39.8)
ULCERATION Positive: 11/58 (19) Positive: 185/808 (23) 0.6259
Negative: 47/58 (81) Negative: 623/808 (77)
MITOSIS Positive: 18/50 (36) Positive: 356/647 (65) 0.0118
Negative: 32/50 (64) Negative: 291/647 (45)
NODE STATUS Positive: 14/68 (20.6) Positive: 278/944 (29.5) 0.1291
Negative: 54/68 (79.4) Negative: 666/944 (70.5)
METASTASES Yes: 6/69 (8.7) Yes: 150/978 (15.3) 0.1619
No: 63/69 (91.3) No: 828/978 (84.7)
BRAF MUTATED 5/7 (71.4) 59/114 (21.8) 0.4449
OTHER TUMOR (NON-SKIN) 6/69 (8.7) 87/978 (8.9) 1
PANCREATIC CANCER IN FAMILY (FIRST &
SECOND DEGREE)
4/69 (5.8) 37/973 (3.8) 0.3422
OTHER TUMORS IN FAMILY (FIRST DEGREE,
NON-SKIN)
30/69 (43.5) 440/978 (45) 0.9005
Bold and italic p-values indicate those variants chosen for the multivariate analysis (only categorical).
doi:10.1371/journal.pone.0124239.t002
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representation. This finding can be explained plausibly using results from a previous work by
Nagore et al. [8], who found a similar proportion of familial melanoma in Valencia (4.3%), in a
single institution study, supporting that, at least in this region, the proportion is similar to that
previously described. Some studies have appointed that there is somehow a higher proportion
of inbreeding in Spain, especially in rural areas [9]. The highest ratio of familial melanoma was
in Navarra (north), but also in Madrid (center), being almost the same in both cases. However,
Madrid, the capital of Spain, has a high heterogeneity in its inhabitant’s origins. Thus, we be-
lieve that there is not a potential influence of inbreeding in our results.
Familial melanoma patients had no significant clinical or pathological differences in the
multivariate analysis compared with that for sporadic melanoma patients. However, univariate
analysis findings require further discussion.
A higher frequency of multiple melanoma was found in patients with familial melanoma.
The disparity between these data and those generated by the multivariate analysis could be
owing to the small number of familial melanoma cases registered, even though this represents
a global sample, as indicated by the clear association between the presence of multiple melano-
ma and germ-line mutations in CDKN2A, as widely described in the literature [10,11]. Recent
studies have reported that relatives of patients with multiple melanoma have a higher risk for
the developing melanoma themselves [12], underlining the importance of the multiple melano-
ma in the familial melanoma context.
A surprising finding was that familial melanoma seemed to have better pathological progno-
sis factors than sporadic melanoma, including lower Breslow indexes, less positive mitoses, and
a trend in less positive lymph nodes. However, it is difficult to assess if these findings reveal a
different biological behavior. Moreover, in addition to the multivariate analysis, two clues de-
scribed in our work may refute the idea that familial melanoma cases have better prognosis than
sporadic melanoma. First, patients with familial melanoma were asked if his or her melanoma
was diagnosed before or after their own relatives’ diagnoses. In all, 68.1% described their diagno-
sis as occurring after their relatives’, suggesting that a greater concern about the disease led to an
earlier diagnosis. Second, familial melanoma patients reported more childhood sunburns than
did sporadic melanoma patients (again not confirmed in the multivariate analysis). These re-
ports could be a result of memory bias of the part of patients expressing concern for the cause of
their melanoma (i.e., if a patient were to associate childhood sunburn with the cause of their
melanoma and remain cognizant of this fact out of concern for other family members). In sup-
port of this, proper counseling and genetic testing among healthy relatives of melanoma patients
has been reported to lead to an increase in self-skin examinations [5] and sunburn prevention
Table 3. Multivariate analysis findings for the association between familial melanoma and variables
of interest.
CLINICAL/PATHOLOGICAL CHARACTERISTIC OR for familial melanoma (95%CI) p VALUE
SEX (MALE) 1.41 (0.7–2.87) 0.340
MULTYPLE NEVI 1.29 (0.53–3.14) 0.576
SUN BURNS IN CHILDHOOD 1.57 (0.71–3.5) 0.267
MULTIPLE MELANOMA 2.64 (0.84–8.33) 0.097
BRESLOW <1 mm 1.65 (0.7–3.84) 0.25
NO MITOSIS 0.78 (0.33–1.83) 0.564
NEGATIVE NODES 0.97 (0.4–2.32) 0.938
NO METASTASES 1.08 (0.31–3.81) 0.906
OR = Odds Ratio.
doi:10.1371/journal.pone.0124239.t003
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[13]. This suggests that people who have experienced melanoma in their families have an in-
creased awareness of the disease, thus explaining in part the earlier diagnoses.
One of the factors that must be taken into account when interpreting the findings of our
work is that no central pathology review was carried out. This could be a source of bias, since
the inter-center variability in the assessment of pathological factors cannot be excluded. It
would have been interesting to analyse other pathological factors of growing interest and poten-
tial differential prognosis. For example, paucity of tumor infiltrating lymphocytes (TILs) seems
to be associated with worse survival outcomes and with a higher frequency of sentinel node
posititivity [14]. One factor of special interest for our research area would be melanin pigmenta-
tion. Although melanin protects against UV radiation, it is described that melanogenesis could
affect the metastatic potential of melanoma, especially in advanced stages. The increase in mela-
nin in pigmented cells lead to changes in cytoskeleton that would make melanoma cells easier to
infiltrate and spread to distant organs [15]. Thus, other non-classical factors should be taken in
consideration in the pathology report. However, in our present work, none of these factors were
analysed. The reason was that no central pathological report was carried out, and findings from
local report were used for the univariate and multivariate analysis for prognostic factors. We
chose those strongly and widely accepted as prognostic (Breslow, mitotic rate, ulceration) in
order to ameliorate the potential inter-center variability with other pathological factors.
Finally, carriers of a CDKN2Amutation have an increased risk for different tumors, with
pancreatic cancer being the most frequently reported, and more recently, smoking-related tu-
mors [16,17]. In this study, we did not detect a higher frequency of other non-skin tumors in
either melanoma patients or their first-degree family members. In the case of pancreatic cancer,
a trend was observed toward a higher frequency in cases of familial melanoma, but this trend
was not statistically significant. It is important to note that the above-mentioned studies were
focused on CDKN2Amutation carriers, who account for only approximately 25% of familial
melanoma cases [3].
In conclusion, we can say that in Spain, according to a representative sample, 6.6% of mela-
noma diagnoses can be considered familial melanoma. Identification of these patients and re-
ferral of the families to cancer genetic counseling and specialized dermatologists must be
included in the global management of melanoma patients. Further studies exploring molecular
and genetic differences between familial and non-familial melanoma are needed for a better
knowledge and management of familial melanoma.
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